Nkcfo LLC Invests $8.04 Million in Medtronic PLC $MDT

Nkcfo LLC purchased a new stake in shares of Medtronic PLC (NYSE:MDT) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 84,400 shares of the medical technology company’s stock, valued at approximately $8,038,000. Medtronic makes up approximately 2.4% of Nkcfo LLC’s investment portfolio, making the stock its 11th biggest position.

Several other institutional investors also recently modified their holdings of MDT. Riverbend Wealth Management LLC raised its position in Medtronic by 3.2% in the 3rd quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock worth $332,000 after buying an additional 107 shares during the last quarter. Holistic Financial Partners grew its stake in shares of Medtronic by 3.0% in the third quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock worth $352,000 after acquiring an additional 109 shares during the period. Wynn Capital LLC raised its holdings in shares of Medtronic by 2.4% during the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after purchasing an additional 110 shares during the last quarter. Meridian Investment Counsel Inc. lifted its position in Medtronic by 0.4% during the third quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock valued at $2,692,000 after purchasing an additional 110 shares during the period. Finally, Saxony Capital Management LLC lifted its position in Medtronic by 3.8% during the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 112 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Morgan Stanley lifted their target price on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Mizuho upgraded Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Daiwa Securities Group upped their price objective on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Sanford C. Bernstein increased their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Finally, Leerink Partners dropped their target price on Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.84.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Medtronic Price Performance

Shares of Medtronic stock opened at $98.54 on Tuesday. The stock has a market cap of $126.33 billion, a P/E ratio of 27.45, a P/E/G ratio of 2.43 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock’s fifty day moving average is $99.03 and its 200 day moving average is $96.80. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the previous year, the company posted $1.38 earnings per share. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is currently 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).